The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing

Although the only effective drug against primary hepatocarcinoma, the multikinase inhibitor Sorafenib (SFB) usually fails to eradicate liver cancer. Since SFB targets mitochondria, cell metabolic reprogramming may underlie intrinsic tumor resistance. To characterize cancer cell metabolic response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Tesori, Valentina, Piscaglia, Anna Chiara, Samengo, Daniela, Barba, Marta, Bernardini, Camilla, Scatena, Roberto, Pontoglio, Alessandro, Castellini, Laura, Spelbrink, Johannes N., Maulucci, Giuseppe, Puglisi, Maria Ausiliatrice, Pani, Giovambattista, Gasbarrini, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361992/
https://www.ncbi.nlm.nih.gov/pubmed/25779766
http://dx.doi.org/10.1038/srep09149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4361992/
https://www.ncbi.nlm.nih.gov/pubmed/25779766
http://dx.doi.org/10.1038/srep09149

Ejemplares similares